Precision Biosciences (DTIL) Current Deferred Revenue (2018 - 2025)
Precision Biosciences (DTIL) posted quarterly Current Deferred Revenue of $6.2 million for Q3 2025, up 3470.29% year-over-year from $175000.0 in Q3 2024, and up 4.32% quarter-over-quarter from $6.0 million in Q2 2025.
Precision Biosciences (DTIL) Current Deferred Revenue (2018 - 2025) Analysis & Trends
Precision Biosciences (DTIL) has reported Current Deferred Revenue for 8 consecutive years, with $6.2 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Current Deferred Revenue rose 3470.29% year-over-year to $6.2 million; the TTM figure through Sep 2025 stood at $6.2 million (up 3470.29% YoY), while the FY2024 annual figure was $3.0 million, down 75.43% from the prior year.
- Current Deferred Revenue rose to $6.2 million in Q3 2025 per DTIL's latest filing, from $6.0 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $53.1 million in Q1 2021 and bottomed at $175000.0 in Q3 2024.
- Historically, Current Deferred Revenue has averaged $20.5 million across 5 years, with a median of $19.7 million in 2022.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue slumped 99.0% — and 2025, when it jumped 3470.29%.
- Precision Biosciences' Current Deferred Revenue stood at $21.2 million in 2021, then soared by 117.44% to $46.2 million in 2022, then tumbled by 73.95% to $12.0 million in 2023, then plunged by 75.43% to $3.0 million in 2024, then jumped by 111.3% to $6.2 million in 2025.
- Business Quant data shows DTIL's Current Deferred Revenue at $6.2 million in Q3 2025, $6.0 million in Q2 2025, and $5.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 6.25 Mn |
| Jun 30, 2025 | 5.99 Mn |
| Mar 31, 2025 | 5.73 Mn |
| Dec 31, 2024 | 2.96 Mn |
| Sep 30, 2024 | 175,000.00 |
| Jun 30, 2024 | 526,000.00 |
| Mar 31, 2024 | 2.41 Mn |
| Dec 31, 2023 | 12.04 Mn |
| Sep 30, 2023 | 17.45 Mn |
| Jun 30, 2023 | 23.81 Mn |
| Mar 31, 2023 | 38.27 Mn |
| Dec 31, 2022 | 46.19 Mn |
| Sep 30, 2022 | 48.41 Mn |
| Jun 30, 2022 | 41.51 Mn |
| Mar 31, 2022 | 19.69 Mn |
| Dec 31, 2021 | 21.24 Mn |
| Sep 30, 2021 | 21.98 Mn |
| Jun 30, 2021 | 22.22 Mn |
| Mar 31, 2021 | 53.09 Mn |
| Dec 31, 2020 | 30.24 Mn |